Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Inflammation in Alzheimer’s Disease

Author(s): Marc Fakhoury*

Volume 17, Issue 11, 2020

Page: [959 - 961] Pages: 3

DOI: 10.2174/156720501711210101110513

« Previous Next »
[1]
Hippius H, Neundörfer G. The discovery of Alzheimer’s disease. Dialogues Clin Neurosci 2003; 5(1): 101-8.
[http://dx.doi.org/10.31887/DCNS.2003.5.1/hhippius] [PMID: 22034141]
[2]
Alzheimer’s Association; What is Alzheimer’s disease? 2020.Available at: ; https://www.alz.org/alzheimers-dementia/what-is-alzheimers(Last accessed September 2020).
[3]
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007; 3(3): 186-91.
[http://dx.doi.org/10.1016/j.jalz.2007.04.381] [PMID: 19595937]
[4]
Armstrong RA. What causes Alzheimer’s disease? Folia Neuropathol 2013; 51(3): 169-88.
[http://dx.doi.org/10.5114/fn.2013.37702] [PMID: 24114635]
[5]
Apostolova LG. Alzheimer Disease Continuum (Minneap Minn) 2016; 22(2 Dementia): 419-34..
[http://dx.doi.org/10.1212/CON.0000000000000307] [PMID: 27042902]
[6]
Medrano M, Rosario RL, Payano AN, Capellán NR. Burden, anxiety and depression in caregivers of Alzheimer patients in the Dominican Republic. Dement Neuropsychol 2014; 8(4): 384-8.
[http://dx.doi.org/10.1590/S1980-57642014DN84000013] [PMID: 29213930]
[7]
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 2017; 17(2): 189-202.
[http://dx.doi.org/10.1080/14737167.2017.1313118] [PMID: 28351177]
[8]
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992; 256(5054): 184-5.
[http://dx.doi.org/10.1126/science.1566067] [PMID: 1566067]
[9]
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2009; 2CD001191
[PMID: 19370562]
[10]
Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD001747
[http://dx.doi.org/10.1002/14651858.CD001747.pub3] [PMID: 16437436]
[11]
Zhang N, Gordon ML. Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients. Clin Interv Aging 2018; 13: 1963-70.
[http://dx.doi.org/10.2147/CIA.S159920] [PMID: 30349215]
[12]
Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One 2015; 10(4)e0123289
[http://dx.doi.org/10.1371/journal.pone.0123289] [PMID: 25860130]
[13]
Alves L, Correia AS, Miguel R, Alegria P, Bugalho P. Alzheimer’s disease: a clinical practice-oriented review. Front Neurol 2012; 3: 63.
[http://dx.doi.org/10.3389/fneur.2012.00063] [PMID: 22529838]
[14]
Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol 2019; 39(2): 227-40.
[http://dx.doi.org/10.1055/s-0039-1678581] [PMID: 30925615]
[15]
Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr 2010; 22(3): 346-72.
[http://dx.doi.org/10.1017/S1041610209991505] [PMID: 20096151]
[16]
Malve HO. Management of Alzheimer’s disease: role of existing therapies, traditional medicines and new treatment targets. Indian J Pharm Sci 2017; 79: 2-15.
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000195]
[17]
De la Rosa A, Olaso-Gonzalez G, Arc-Chagnaud C, et al. Physical exercise in the prevention and treatment of Alzheimer’s disease. J Sport Health Sci 2020; 9(5): 394-404.
[http://dx.doi.org/10.1016/j.jshs.2020.01.004] [PMID: 32780691]
[18]
Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disorder 2013; 6(1): 19-33.
[http://dx.doi.org/10.1177/1756285612461679] [PMID: 23277790]
[19]
Wang H, Shen Y, Chuang H, Chiu C, Ye Y, Zhao L. Neuroinflammation in Alzheimer’s disease: microglia, molecular participants and therapeutic choices. Curr Alzheimer Res 2019; 16(7): 659-74.
[http://dx.doi.org/10.2174/1567205016666190503151648] [PMID: 31580243]
[20]
Fakhoury M. Microglia and astrocytes in Alzheimer’s disease: implications for therapy. Curr Neuropharmacol 2018; 16(5): 508-18.
[http://dx.doi.org/10.2174/1570159X15666170720095240] [PMID: 28730967]
[21]
Peña-Ortega F. Brain arrhythmias induced by amyloid beta and inflammation: involvement in Alzheimer’s disease and other inflammation-related pathologies. Curr Alzheimer Res 2019; 16(12): 1108-31.
[http://dx.doi.org/10.2174/1567205017666191213162233] [PMID: 31838994]
[22]
Ceyzériat K, Zilli T, Millet P, Frisoni GB, Garibotto V, Tournier BB. Learning from the past: a review of clinical trials targeting amyloid, tau and neuroinflammation in Alzheimer’s disease. Curr Alzheimer Res 2020; 17(2): 112-25.
[http://dx.doi.org/10.2174/1567205017666200304085513] [PMID: 32129164]
[23]
Liu D, Zhao D, Zhao Y, Wang Y, Zhao Y, Wen C. Inhibition of microRNA-155 alleviates cognitive impairment in Alzheimer’s disease and involvement of neuroinflammation. Curr Alzheimer Res 2019; 16(6): 473-82.
[http://dx.doi.org/10.2174/1567205016666190503145207] [PMID: 31456514]
[24]
Sastre M, Gentleman SM. NSAIDs: how they work and their prospects as therapeutics in Alzheimer’s disease. Front Aging Neurosci 2010; 2: 20.
[http://dx.doi.org/10.3389/fnagi.2010.00020] [PMID: 20589102]
[25]
Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer’s disease: old and new mechanisms of action. J Neurochem 2004; 91(3): 521-36.
[http://dx.doi.org/10.1111/j.1471-4159.2004.02743.x] [PMID: 15485484]
[26]
Szczepanik AM, Ringheim GE. IL-10 and glucocorticoids inhibit Abeta(1-42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis 2003; 5(2): 105-17.
[http://dx.doi.org/10.3233/JAD-2003-5205] [PMID: 12719628]
[27]
Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54(3): 588-93.
[http://dx.doi.org/10.1212/WNL.54.3.588] [PMID: 10680787]
[28]
de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One 2008; 3(1): e1475
[http://dx.doi.org/10.1371/journal.pone.0001475] [PMID: 18213383]
[29]
Townsend KP, Praticò D. Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005; 19(12): 1592-601.
[http://dx.doi.org/10.1096/fj.04-3620rev] [PMID: 16195368]
[30]
Kim J, Kim YK. Inflammatory biomarkers in AD: implications for diagnosis. Curr Alzheimer Res 2020; 17(11): 962-71.
[31]
Culjak M, Perkovic MN, Uzun S, et al. The association between TNF-alpha, IL-1 alpha and IL-10 with Alzheimer’s disease. Curr Alzheimer Res 2020; 17(11): 972-84.
[PMID: 33256580]
[32]
Vaz M, Domingues C, Trindade D, et al. IL-8 and MCP-1 impact on tau phosphorylation and phosphatase activity. Curr Alzheimer Res 2020; 17(11): 985-1000.
[PMID: 33256579]
[33]
Ali Ahmad RHH, Fakhoury M, Lawand NB. Electromagnetic field in Alzheimer’s disease: a literature review of recent preclinical and clinical studies. Curr Alzheimer Res 2020; 17(11): 1001-12.
[34]
Villarejo-Galende A, González-Sánchez M, Blanco-Palmero VA, Velasco SL, Benito-León J. Non-steroidal anti-inflammatory drugs as candidates for the prevention or treatment of Alzheimer’s disease: do they still have a role? Curr Alzheimer Res 2020; 17(11): 1013-22.
[PMID: 33245273]

Rights & Permissions Print Cite
Article Metrics
22
© 2024 Bentham Science Publishers | Privacy Policy